BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 27, 2006
 |  BioCentury  |  Finance

EPS watch

EPS watch

EPS watch
Investors jumped into BioMarin (BMRN) after the company's loss per share was less than the Street was expecting, driven by sales of the company's enzyme replacement therapies. On the downside, cardiovascular company Kos (KOSP) took a 16% haircut after its 4Q numbers missed analyst estimates. Moreover, KOSP told investors that one-time expenses will dig into earnings in 2006. Mcap in $M
Company 4Q05 EPS est 4Q05 EPS actual Outcome Growth from 4Q04 2/24 cls Wk chg % chg Mcap chg 2/24 Mcap
Actelion (SWX:ATLN) NA

Read the full 527 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >